Oncology

Latest News

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

September 6th 2025

Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com
NOTCH1 Levels Impact Immune Response in SCLC

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe
Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

August 31st 2025

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com
Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

August 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity
October 18th 2018

What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity

AJMC Staff
UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs; Express Scripts has decided it will cover Eli Lilly’s and Amgen’s migraine drugs and will not cover Teva Pharmaceutical's drug; black men are more likely to get and die from prostate cancer compared with white men, but they are underrepresented in prostate cancer research because of a general distrust of the healthcare system.
Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity
October 18th 2018

Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity

Jaime Rosenberg
A study has found no evidence that bleomycin plus granulocyte-stimulating factor (G-CSF) increases the risk for bleomycin-induced pulmonary toxicity in patients with Hodgkin lymphoma.
Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial
October 17th 2018

Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial

Samantha DiGrande
Last week, Bristol-Myers Squibb announced results from the phase 3 CheckMate -331 trial that investigated nivolumab (Opdivo) versus the current standard of care, chemotherapy, in the treatment of patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. The trial found that nivolumab did not significantly increase overall survival compared with chemotherapy.
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17th 2018

Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.
Site Logo
October 16th 2018

Nurse Practitioners Can Lead the Way in Affecting Colorectal Cancer Screening

A recent survey investigates the role nurse practitioners can play to promote colorectal cancer screening.
Site Logo
October 16th 2018

Squaring Value-Based Payment With Innovation in Oncology

Mary Caffrey
Finding a place for value-based payment with the fast paced innovation in oncology.
Site Logo
October 16th 2018

Medical Marijuana in Cancer Treatment: No Standards of Care, and So Far, No Coverage

Samantha DiGrande
Over the past decade, both recreational and medical marijuana use in the United States has grown tremendously. However, disputes surrounding the legal and ethical implications, safe administration, dispensing, health consequences, and therapeutic indications– albeit based on very limited clinical data– related to its usage abound.
Site Logo
October 15th 2018

Patient Satisfaction Surveys: A Continuous NCODA Initiative for Improvement Within the Oncology Dispensing Practice

Joshua J. Nubla, PharmD Robert D. Orzechowski, MBA Aaron Budge, PharmD
NCODA presents findings from over 700 patient responses across the country to determine patient satisfaction over 4 categories: time, convenience, staff interaction, and overall satisfaction.
Site Logo
October 15th 2018

Survey of NCI-Designated Cancer Centers Finds Most Are Out-of-Network on Exchanges

Alyssa Schatz, MSW Katy Winckworth-Prejsnar, MPH
The National Comprehensive Cancer Network (NCCN) in collaboration with Avalere Health present survey results examining the experiences National Cancer Institute (NCI)-designated cancer centers have had with the marketplaces, the implications for patients' access to cancer care, and proposed policy solutions.
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14th 2018

Three Genetic Types Drive Higher Prevalence of MM in African Americans

Laura Joszt, MA
Multiple myeloma (MM) occurs 2 to 3 times more frequently in Americans of African descent than in Americans of European descent, and a new study has identified 3 gene types that account for this disparity.
ACOs Had No Significant Impact on Spending for Patients With Cancer
October 14th 2018

ACOs Had No Significant Impact on Spending for Patients With Cancer

Laura Joszt, MA
Accountable care organizations (ACOs) have not had a significant impact on cancer care costs and utilization. While cancer care costs did decline from before the introduction of ACOs to after, there was no significant difference in spending decreases between ACO practices and non-ACO practices caring for patients with cancer.
Know the Risk: 5 Breast Cancer Risk Factors
October 13th 2018

Know the Risk: 5 Breast Cancer Risk Factors

Samantha DiGrande
Here are 5 breast cancer risk factors for Breast Cancer Awareness Month.
The US Oncology Network Announces Highly Positive MIPS Results for 2017
October 12th 2018

The US Oncology Network Announces Highly Positive MIPS Results for 2017

Laura Joszt, MA
Practices in the US Oncology Network received an average positive payment adjustment under the Merit-based Incentive Payment System (MIPS) of 1.90% for performance in 2017, and 99% of the Network’s physicians were in the top tier of performers. The maximum allowable adjustment is 2.02%. The adjustment based on a clinician’s performance in 2017 impacts the clinician's Medicare reimbursement for 2019.
Nobel Prize Winner Dr James Allison Discusses the Need to Fund More Fundamental Science
October 12th 2018

Nobel Prize Winner Dr James Allison Discusses the Need to Fund More Fundamental Science

Major discoveries only happen when there is funding for fundamental science, said James Allison, PhD, chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for Cancer Research, executive director of the Immunotherapy Platform at MD Anderson Cancer Center, and 2018 Nobel Prize cowinner in Medicine. He explained that he never would have discovered how to use the CTLA-4 protein to treat cancer if he hadn’t been trying to understand the mechanisms of T-cell activation.
Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds
October 11th 2018

Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds

Laura Joszt, MA
Tisagenlecleucel's high price is aligned with the benefit the chimeric antigen receptor T-cell therapy provides over a patient's life. Approximately 40% of patients treated are expected to be long-term survivors.
NCCN Releases Patient Guidelines for Neuroendocrine Tumors
October 10th 2018

NCCN Releases Patient Guidelines for Neuroendocrine Tumors

Samantha DiGrande
This week, the National Comprehensive Cancer Network (NCCN) published new guidelines for patients centered around neuroendocrine tumors.
FDA Approves Libtayo to Treat Second Most Common Skin Cancer
October 10th 2018

FDA Approves Libtayo to Treat Second Most Common Skin Cancer

Samantha DiGrande
Last week, the FDA granted approval to immune checkpoint inhibitor cemiplimab-rwlc, to be sold as Libtayo, for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), or in patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Some Metro Areas Facing Shortages of Oncologists in Coming Years, Report Says
October 10th 2018

Some Metro Areas Facing Shortages of Oncologists in Coming Years, Report Says

Allison Inserro
A medical social network for physicians said it has compiled data that pinpoint the top 50 metropolitan areas where shortages of oncologists are expected to occur in the coming years. Doximity said the findings in its 2018 National Oncologists Workforce report are drawn from retirement trends, the percentage of state-trained specialists, and the prevalence of breast cancer.
Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?
October 8th 2018

Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?

David Bai
The development of resistance to immunotherapy is poorly understood and is detrimental to patients who relapse on multiple lines of treatment. Transcriptional downregulation of class 1 human leukocyte antigen (HLA) may contribute to the developed resistance of immunotherapies, including checkpoint inhibitors, and warrants further investigation, according to a study published in Nature Communications.
Site Logo
October 7th 2018

A Comprehensive Look at Updates, Developments in NETs

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlined the biggest news and updates in the treatment of neuroendocrine tumors (NETs).
Site Logo
October 7th 2018

An Update on Lung NET Guidelines

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society (NANETS) annual meeting, held October 4-6 in Seattle, Washington, Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, gave an overview of updates made to lung neuroendocrine tumor guidelines.
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 7th 2018

Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses peptide receptor radionuclide therapy and other new and exciting developments in the treatment of neuroendocrine tumors (NETs).
Site Logo
October 6th 2018

Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs

AJMC Staff
A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide after octreotide can be a potential therapeutic option.
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 6th 2018

Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape

The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Site Logo
October 6th 2018

Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options

Jaime Rosenberg
Narrowing in on neuroendocrine skin cancer, a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, took an in-depth look at prognostics and treatment options for Merkel cell carcinoma in the United States.
Site Logo
October 6th 2018

Debating Best First-Line Treatment in Well-Differentiated G3 NENs

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists debated whether newer targeted agents should be considered for first-line treatment in well-differentiated G3 neuroendocrine neoplasms (NENs), and if the standard of care—cytotoxic therapy—should still play a role in first-line treatment.
Cancer Types Can Impact How Well Providers May Perform Under OCM
October 5th 2018

Cancer Types Can Impact How Well Providers May Perform Under OCM

Laura Joszt, MA
The type of cancer a provider treats can determine how well he or she performs under the Oncology Care Model (OCM), according to research from Avalere Health that was presented at the American Society of Clinical Oncology Quality Care Symposium.
Site Logo
October 5th 2018

Examining the Benefits of Integrative Oncology, Nutrition in NETs

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists discussed the benefits of integrative oncology and nutrition for patients with neuroendocrine tumors.
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 5th 2018

Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs

Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
Site Logo
October 5th 2018

Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs

Jaime Rosenberg
An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.
<1
...
394041424344454647
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo